Fig. 7.
In vivo tumour therapy study. Pseudo-metastatic lung A375Pβ6 tumour bearing mice were treated with L-ALD (0.5 μmol ALD/mouse), 1 × 107 γδ T cells/mouse or both, intravenously. Three treatments were given intravenously at one week intervals, commencing on day 6 post-tumour inoculation. Tumour progression was monitored by bioluminescence imaging. A significant reduction in tumour growth was observed for the combinatory immunotherapy. Data was expressed as mean ± SEM (n = 7). *p < 0.05, (Student's t-test vs. naïve).